Welcome to our dedicated page for Precision BioSciences news (Ticker: $DTIL), a resource for investors and traders seeking the latest updates and insights on Precision BioSciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Precision BioSciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Precision BioSciences's position in the market.
News
Rhea-AI Summary
Precision BioSciences (DTIL) grants Caribou Biosciences a license for gene editing therapy patents. The agreement includes upfront payment, royalties, and milestone payments for commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.28%
Tags
-
Rhea-AI Summary
Precision BioSciences receives positive regulatory feedback for PBGENE-HBV program, advancing towards clinical development. Expected to be the first potentially curative gene editing program targeting Chronic Hepatitis B.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.47%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) promotes Naresh Tanna to Vice President of Investor Relations to enhance and expand its IR program. Tanna, with over 18 years of diverse experience in Oncology, Infectious Diseases, and Rare Diseases, will lead communications with shareholders. His promotion follows Mei Burris' elevation to Senior Director of Finance and Corporate Controller in September 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
Rhea-AI Summary
Precision BioSciences (DTIL) receives upfront cash payment and equity investment from TG Therapeutics (TGTX) for an exclusive license to develop Azercabtagene Zapreleucel for autoimmune diseases, with potential payments totaling $17.5 million. Precision also expects to receive up to $288 million in milestone payments and royalties on net sales, extending its cash runway into the first half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2830.47%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announces a 1-for-30 reverse stock split to increase per share market price and meet Nasdaq listing requirements. The split will be effective on February 13, 2024, with trading under the existing symbol 'DTIL'. Shareholders will receive one new share for every 30 shares held.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) has completed a strategic transaction with TG Therapeutics, Inc. to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases. Precision will receive $17.5 million upfront and near-term payments, with potential for up to $288 million in other development milestone payments. The upfront cash and near-term payments are expected to extend Precision’s cash runway into the first half of 2026 and fund Precision’s Wholly-Owned In Vivo Gene Editing Programs through PBGENE-HBV and PBGENE-PMM Phase I Clinical Data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.1%
Tags
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) partner iECURE receives clearance from Australian Therapeutic Goods Administration for Phase 1/2 study of ECUR-506 for the treatment of Ornithine Transcarbamylase (OTC) deficiency. The approval marks a significant milestone for patients and the company, with promising preclinical results indicating the potential for a curative treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
-
Rhea-AI Summary
iECURE, Inc. (ECUR) announced that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Clinical Trial Notification (CTN) for ECUR-506, an investigational therapy for the treatment of Ornithine Transcarbamylase (OTC) deficiency in pediatric patients. The CTN approval represents the first of such regulatory approvals to begin clinical trials, with additional approvals expected in 2024. The company is in the process of preparing sites for the global, first-in-human Phase 1/2 clinical study and anticipates initiation of such clinical trial in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announced the publication in Nature Metabolism of a peer-reviewed manuscript supporting the development of the PBGENE-PMM in vivo gene editing program as a potentially curative therapeutic approach for patients with m.3243-associated primary mitochondrial myopathy. The publication validates the unique ability of ARCUS genome editing to target and eliminate mutant m.3243G mitochondrial DNA with high specificity, leading to an overall improvement in mitochondrial function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) will present at Hep-DART 2023 in Los Cabos, Mexico, showcasing their PBGENE-HBV Program for gene editing therapies to potentially cure chronic hepatitis B. Presenters include Jeff Smith, Co-Founder and Chief Research Officer, and Emily Harrison, HBV Research Lead.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
Precision BioSciences, Inc.
Nasdaq:DTIL
DTIL Rankings
DTIL Stock Data
72.76M
5.24M
8.48%
39.81%
4.18%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
DURHAM
About DTIL
precision biosciences, inc. is a biotechnology company located in durham, north carolina, united states.